Re: Dirk Blog
The part that interested me was his speculation about the triggers. DPC had 520 and 521 aimed at different sequences and had a different impact on integrated and CCC sAG.
TRiM uses two new triggers optimized so ARO-HBV can hit all 4 subgroups of patients and the Abstract shows the new formulation is working very well, but it still has not fine tuned the question of dose response for each patient subgroup.
The question I think Dirk is asking is whether a single drug is the best way to address all subgroups, and he is suggesting, perhaps, that the patient should be classified into a subgroup, and then receive a drug optimized slightly differently for one or more of the subgroups.
For example, if one group has early stage disease without integrated viral DNA, would a 520 type trigger be more effective?